Stryker Corporation reported second-quarter net sales of $6.6 billion, up 9.4% year over year, with organic sales up 9% and adjusted earnings up 17.9% to $3.69 per share. Adjusted operating margin reached 27.4%, up 170 basis points year over year, as MedSurg and Neurotechnology grew 9.2% organically and Orthopaedics advanced 8.6%. Management narrowed its 2026 organic sales growth outlook to 8.3%-9.3% and adjusted earnings guidance to $14.95-$15.10 per share, assuming continued recovery execution after the first-quarter cybersecurity disruption. The company exited the quarter with elevated backlog and strong orders, including Mako's best-ever second quarter for installations in both the United States and international markets, though cyber remediation costs and a Peripheral Vascular supply disruption remain risks.
Stryker CorporationStrong Q2 results and narrowed guidance indicate recovery and improved outlook.
Intuitive Surgical Inc
Zimmer Biomet Holdings Inc